Latest From Premier Inc.
The administration's nominee to head HHS is being praised by medtech health-care industry lobbyists but may experience some pushback in the Senate because of his ties to Eli Lilly.
With two biosimilars set to move into Phase III this year, Oncobiologics hopes partnership with hospital services firm Premier will generate 'best practices around the optimal use of these cost-effective treatments.'
In Premier Inc.’s new survey, hospitals and health systems project a significant shift in 2013 admissions from inpatient to outpatient settings as these sites transition toward new care delivery models.
A recent article funded by the National Pharmaceutical Council asserts that the success of value-based health care delivery models such as accountable care organizations will require viewing pharmaceuticals as a tool that can reduce total costs and improve quality, rather than a siloed expense.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Premier Inc.
- Senior Management
Robert W O'Leary, Chmn. & CEO
Jill O Freeman, VP, Member Relations
Bary G Bailey, EVP, Fin.
Douglas L Collins, VP, Energy Services
- Contact Info
Phone: (704) 357-0022
2320 Cascade Pointe Blvd
Charlote, NC 28208
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.